Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Moffitt Cancer Center
•
HR+
•
NCI-CCC Breast Tumor Board Question
•
Breast Cancer, Non-metastatic
How do you manage adjuvant endocrine therapy for pre-menopausal women with locally advanced, weakly positive ER/PR, HER2 negative breast cancer?
Would a pCR to neoadjuvant chemotherapy change your management? (ER <5%, PR <5%)
Answer from: Medical Oncologist at Community Practice
Likely very little benefit. Reasonable to try tamoxifen if tolerated.
Sign In
or
Register
to read more
9768
Related Questions
What is your approach to adjuvant chemotherapy for a postmenopausal woman with pT1cN0 grade 2 ER+ breast cancer (IDC) and OncoType RS of 25?
What are your top takeaways in Medical Oncology from SABCS 2024?
In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/HER2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
How do you treat ER/PR + DCIS with no identified invasive component that has microscopic sentinel lymph node metastasis? Would you complete HER2 staining on original specimen?